Drugs / CD19/BCMA in vivo CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07388212 | Feb 2026 → Jan 2028 expected | autoimmune disease | West China Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA in vivo CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07388212 ↗ |
| Action | Deplete | “clearing B cells” NCT07388212 ↗ |
| Modality | Messenger RNA (mRNA) | “messenger ribonucleic acid (mRNA) therapeutic drug” NCT07388212 ↗ |
| Route | Intramuscular | “through intravenous or intramuscular injection” NCT07388212 ↗ |
| Route | Intravenous | “through intravenous or intramuscular injection” NCT07388212 ↗ |
| Target | CD19 | “dual targets of CD19 and BCMA” NCT07388212 ↗ |